# Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

> **NCT02577016** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 141 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo
- **DRUG:** Ipragliflozin

## Key facts

- **NCT ID:** NCT02577016
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-05
- **Primary completion:** 2016-11-18
- **Final completion:** 2016-11-18
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577016, "Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02577016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*